Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.
FIGO stage I-II with a known BRCA1/2 mutation (germline/gBRCA or somatic/tBRCA) [+5]
Non-epithelial ovarian cancer, borderline tumors, or mucinous histology [+1]